Using nanopocket membranes to capture bacterial outer membrane vesicles from biofluids
Using nanopocket membranes to capture bacterial outer membrane vesicles from biofluids
批准号:
10425443
负责人:
THOMAS R GABORSKI
金额:
$18.44万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-06-09 至 2024-05-31
关键词:
APACHE IIAgeAlbuminsAntibioticsAntibodiesAntigensBacteriaBenchmarkingBiologicalBiological MarkersCause of DeathCellsChronicClinicalClinical DataComplexCritical CareCulture MediaDevelopmentDiagnosisDiagnosticDiagnostic ProcedureDiagnostic testsEarly treatmentEnterobacteriaceaeEscherichia coliFiltrationFocal InfectionFutureHealth StatusHospitalsHourHumanImmune responseInfectionInflammatoryLiquid substanceMeasuresMembraneMolecular Diagnostic TestingOrganismOutcomeParentsPatientsPhosphate BufferPhysiciansPhysiologicalPlasmaProteinsRadialRetrospective StudiesSalineSamplingScientistSepsisSeverity of illnessSystemTechniquesTechnologyTestingTissuesUltracentrifugationVariantVesicleWorkdetection methoddiagnostic assaydiagnostic biomarkerextracellular vesiclesmolecular diagnosticsmolecular markermortalitynovelpoint of carepoint-of-care diagnosticspotential biomarkerpressurerapid diagnosisseptic patientssuccesstool
中文摘要
项目摘要
败血症不仅是美国医院治疗费用最高的疾病,
死亡之当宿主的促炎免疫反应变得异常时,
由于宿主对感染的反应失调或异常而升高。诊断方法
脓毒症在不同的医院可能有所不同,但通常涉及评分系统(例如APACHE II和SOFA)
对病人的病情进行分级。许多改变的生理参数
通过这些评分系统测量的不一定是脓毒症特有的,这使得很难
早期诊断败血症患者脓毒症诊断的时间通常可以预测
他们的临床结果,强调需要一个更明确的分子诊断测试。
然而,最近的一项研究发现,在大多数(70.1%)脓毒症病例中,
无法确定微生物,可能是由于侵袭性抗生素或局部感染。
细菌外膜囊泡(OMV)是有吸引力的诊断生物标志物,因为:
它们的丰富性和在整个身体中循环的能力以及更容易通过组织屏障
B)它们的鲁棒性-与它们的细菌细胞“亲本”不同,OMV可以
能够抵抗广谱抗生素的泛滥;以及C)它们的独特功能,
允许细菌物种之间的区分。
这项提议的目的是双重的:确定细菌OMV是否可能是一种分子,
因此,本发明提供了用于脓毒症的诊断生物标志物,并开发了从患者血浆中分离它们的快速方法。
我们寻求开发一种简单的高纯度和快速分离技术,
从包括血浆在内的生物流体中分离和纯化OMV。我们将实施一项修改后的
切向流过滤方法,类似于生物制药公司用于高容量和高
产量纯化,采用新的纳米口袋膜,有效地捕获和释放
细菌OMV,损失最小。这些目标的成功将为未来铺平道路
使用细菌OMV作为败血症的一步式即时诊断试验的开发
分子生物标志物,以及更复杂的诊断测试,更准确地量化OMV
患者的生物液体中的水平,以帮助指导早期治疗和降低死亡率。该项目将
由一个跨学科的专家小组领导,在E.大肠杆菌;
膜,材料和生物分离;和重症监护医生科学家。
英文摘要
PROJECT SUMMARY
Sepsis is not only the most expensive condition treated in US hospitals, but also a leading cause
of death. Sepsis occurs when host pro-inflammatory immune responses become abnormally
elevated due to a dysregulated or aberrant host-response to infection. Diagnostic methods for
sepsis can vary between hospitals, but often involve scoring systems (e.g. APACHE II and SOFA)
that grade the severity of illness in patients. Many of the altered physiological parameters
measured by these scoring systems are not necessarily specific to sepsis, which makes it difficult
to diagnose sepsis in early stages. Timing of a patient’s sepsis diagnosis is often predictive of
their clinical outcome, underlining the need for a more definitive molecular diagnostic test.
However, a recent study found that in the majority (70.1%) of sepsis cases, a specific causal
organism could not be determined, likely due to aggressive antibiotics or localized infections.
Bacterial outer membrane vesicles (OMVs) are attractive diagnostic biomarkers because of: A)
their abundance and ability to circulate throughout the body and pass tissue barriers more easily
than bacteria themselves; B) their robustness - unlike their bacterial cell “parent,” OMVs can
withstand the inundation of broad-spectrum antibiotics; and C) their unique features that could
allow for differentiation between bacterial species.
The objective of this proposal is two-fold: Identify whether bacterial OMVs could be a molecular
diagnostic biomarker for sepsis and develop a rapid approach to isolate them from patient plasma.
We seek to develop a straightforward high-purity and rapid separation technology that effectively
isolates and purifies OMVs from biofluids, including plasma. We will implement a modified
tangential flow filtration approach, similar to those used by biopharma for high-capacity and high-
yield purification, with a new nanopocket membrane that effectively captures and releases
bacterial OMVs with minimal loss. Success of these aims will pave the way for the future
development of a one-step, point-of-care diagnostic test for sepsis using bacterial OMVs as the
molecular biomarker, as well a more complex diagnostic test that more accurately quantifies OMV
levels in the patient’s biofluids to help direct early treatment and reduce mortality. This project will
be led by an interdisciplinary team of experts in identifying potential biomarkers in E. coli;
membranes, materials, and bioseparations; and a critical care physician scientist.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2022
期刊:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子:
--
作者:
[Dinu,MilenaA, Michel,Lea, Gaborski,Thomas, Perdue,Janai, Kasper,Anna, Morehouse,Ryan]
通讯作者:
Morehouse,Ryan
Triggering toxicity: How antibiotics can enhance the release of outer membrane vesicles from Escherichia coli during sepsis.
引发毒性:抗生素如何在败血症期间增强大肠杆菌外膜囊泡的释放。
DOI:
--
发表时间:
2022
期刊:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子:
--
作者:
[Michel,LeaV, Konovalova,Anna, Hellman,Judith, Gaborski,Thomas]
通讯作者:
Gaborski,Thomas
Optimizing the production, purification, characterization of E. coli OMVs.
优化大肠杆菌 OMV 的生产、纯化和表征。
DOI:
--
发表时间:
2022
期刊:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子:
--
作者:
[Kasper,Anna, Henretta,Sarah, Dinu,Milena, Smith,Callum, Videva,Martina, Crawford,Jamie, Shanahan,Caitlin, Gaborski,Thomas, Michel,LeaV]
通讯作者:
Michel,LeaV
Investigating the Application of Size-Exclusion Chromatography to Purify Bacterial Extracellular Vesicles.
研究尺寸排阻色谱法在纯化细菌细胞外囊泡中的应用。
DOI:
--
发表时间:
2022
期刊:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子:
--
作者:
[Gaborski,Thomas, Guernsey,Cara, Henretta,Sara, Hosseinifakhr,Atiyeh, Torabian,Pantea, Kasper,Anna, Michel,Lea]
通讯作者:
Michel,Lea
DOI:
10.1016/j.jbc.2022.102483
发表时间:
2022-10
期刊:
JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子:
4.8
作者:
[Michel, Lea Vacca, Gaborski, Thomas]
通讯作者:
Gaborski, Thomas
Development of size-selective capture and release membranes for purification of extracellular vesicles
-
批准号:10631914
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2022
-
负责人:THOMAS R GABORSKI
-
依托单位:
Development of size-selective capture and release membranes for purification of extracellular vesicles
-
批准号:10432803
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2022
-
负责人:THOMAS R GABORSKI
-
依托单位:
Using nanopocket membranes to capture bacterial outer membrane vesicles from biofluids
-
批准号:10288527
-
项目类别:
-
资助金额:$23.26万
-
财政年份:2021
-
负责人:THOMAS R GABORSKI
-
依托单位:
Plasma clearance of water soluble and albumin bound toxins using graphene oxide nanoengineered laminates
-
批准号:9387567
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2017
-
负责人:THOMAS R GABORSKI
-
依托单位:
Transparent Ultrathin Nanomembranes for Barrier Cell Models and Novel Co-Culture Systems
-
批准号:9336323
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2016
-
负责人:THOMAS R GABORSKI
-
依托单位:
Nanoporous Membranes for cellular microarrays and in vitro assays
-
批准号:8200228
-
项目类别:
-
资助金额:$18.47万
-
财政年份:2011
-
负责人:THOMAS R GABORSKI
-
依托单位:
Microfabricated porous TEM grids for improved phase contrast and CryoEM imaging
-
批准号:8252786
-
项目类别:
-
资助金额:$15.58万
-
财政年份:2011
-
负责人:THOMAS R GABORSKI
-
依托单位:
Nanoporous silicon membranes for protein purification
-
批准号:7802530
-
项目类别:
-
资助金额:$15.32万
-
财政年份:2010
-
负责人:THOMAS R GABORSKI
-
依托单位:
Analysis of Physical Mechanisms in Cell Adhesion
-
批准号:7072824
-
项目类别:
-
资助金额:$4.17万
-
财政年份:2005
-
负责人:THOMAS R GABORSKI
-
依托单位:
Analysis of Physical Mechanisms in Cell Adhesion
-
批准号:6935087
-
项目类别:
-
资助金额:$4.17万
-
财政年份:2005
-
负责人:THOMAS R GABORSKI
-
依托单位:
Analysis of Physical Mechanisms in Cell Adhesion
-
批准号:7233662
-
项目类别:
-
资助金额:$4.17万
-
财政年份:2005
-
负责人:THOMAS R GABORSKI
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: